Gland Pharma Limited Market Cap ($5.47 Billion)
Market Cap & Net Worth: Gland Pharma Limited (GLAND)
Gland Pharma Limited market cap. Gland Pharma Limited (NSE:GLAND) has a market capitalization of $5.47 Billion (Rs506.02 Billion) as of November 3, 2026. Listed on the NSE stock exchange, this India-based company holds position #3267 globally and #143 in its home market, demonstrating a 8.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gland Pharma Limited's stock price Rs3066.60 by its total outstanding shares 165010854 (165.01 Million). Also see GLAND cash generation efficiency for how efficiently the company converts equity into cash flow.
Gland Pharma Limited Market Cap History (2020–2026)
Gland Pharma Limited market cap history from 2020 to 2026. Data shows growth from $4.13 Billion to $5.47 Billion (9.35% CAGR). Check latest Gland Pharma Limited stock price today for real-time trading data and today's change.
Index Memberships
Gland Pharma Limited is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$103.02 Billion | 5.31% | #9 of 20 |
|
NIFTY 500
NIFTY500
|
$2.99 Trillion | 0.18% | #134 of 500 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$657.41 Billion | 0.83% | #51 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.08 Trillion | 0.51% | #64 of 400 |
|
NIFTY MNC
NIFTYMNC
|
$209.14 Billion | 2.62% | #12 of 30 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.08 Trillion | 0.18% | #132 of 750 |
Weight: Gland Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gland Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gland Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Gland Pharma Limited (GLAND) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
Gland Pharma Limited's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.53x
Gland Pharma Limited's market cap is 0.53 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.13 Billion | $26.33 Billion | $7.73 Billion | 0.16x | 0.53x |
| 2021 | $6.83 Billion | $34.63 Billion | $9.97 Billion | 0.20x | 0.68x |
| 2022 | $2.78 Billion | $44.01 Billion | $12.12 Billion | 0.06x | 0.23x |
| 2023 | $3.40 Billion | $36.25 Billion | $7.81 Billion | 0.09x | 0.44x |
| 2024 | $3.18 Billion | $56.65 Billion | $7.72 Billion | 0.06x | 0.41x |
| 2025 | $3.07 Billion | $56.17 Billion | $6.99 Billion | 0.05x | 0.44x |
| 2026 | $5.47 Billion | $64.31 Billion | $10.27 Billion | 0.09x | 0.53x |
Competitor Companies of GLAND by Market Capitalization
Companies near Gland Pharma Limited in the global market cap rankings as of November 3, 2026. Also see GLAND total assets for a full breakdown of the balance sheet.
Key companies related to Gland Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Gland Pharma Limited (2020–2026)
Market capitalization of Gland Pharma Limited from 2020 to today. Between 2020 and today, Gland Pharma Limited's market cap moved from $4.13 Billion to $ 5.47 Billion, with a yearly change of 9.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs5.47 Billion | +78.08% |
| 2025 | Rs3.07 Billion | -3.22% |
| 2024 | Rs3.18 Billion | -6.59% |
| 2023 | Rs3.40 Billion | +22.07% |
| 2022 | Rs2.78 Billion | -59.20% |
| 2021 | Rs6.83 Billion | +65.17% |
| 2020 | Rs4.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Gland Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.47 Billion USD |
| MoneyControl | $5.47 Billion USD |
| MarketWatch | $5.47 Billion USD |
| marketcap.company | $5.47 Billion USD |
| Reuters | $5.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The … Read more